222 related articles for article (PubMed ID: 9649138)
1. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
Abdel-Fattah R; Challen C; Griffiths TR; Robinson MC; Neal DE; Lunec J
Br J Cancer; 1998 Jun; 77(12):2230-8. PubMed ID: 9649138
[TBL] [Abstract][Full Text] [Related]
2. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
3. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.
Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X
Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112
[TBL] [Abstract][Full Text] [Related]
4. Deletion/duplication mutation screening of TP53 gene in patients with transitional cell carcinoma of urinary bladder using multiplex ligation-dependent probe amplification.
Bazrafshani MR; Nowshadi PA; Shirian S; Daneshbod Y; Nabipour F; Mokhtari M; Hosseini F; Dehghan S; Saeedzadeh A; Mosayebi Z
Cancer Med; 2016 Feb; 5(2):145-52. PubMed ID: 26685928
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
Schlichtholz B; Presler M; Matuszewski M
Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
[TBL] [Abstract][Full Text] [Related]
6. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.
Friedrich MG; Riethdorf S; Erbersdobler A; Tiemer C; Schwaibold H; Sölter JK; Huland E; Riethdorf L; Conrad S; Hammerer PG; Huland H
Eur Urol; 2001 Feb; 39(2):159-66. PubMed ID: 11223675
[TBL] [Abstract][Full Text] [Related]
7. TP53 and p21WAF1/CIP1 behave differently in euploid versus aneuploid bladder tumours treated with radiotherapy.
Røtterud R; Skomedal H; Berner A; Danielsen HE; Skovlund E; Fosså SD
Acta Oncol; 2001; 40(5):644-52. PubMed ID: 11669339
[TBL] [Abstract][Full Text] [Related]
8. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
[TBL] [Abstract][Full Text] [Related]
9. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
[TBL] [Abstract][Full Text] [Related]
11. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
[TBL] [Abstract][Full Text] [Related]
12. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
[TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of the p53 tumor suppressor gene using paraffin-embedded specimens of human transitional cell carcinomas by the direct sequencing method.
Masuda A; Kikuchi YY; Kawamura N
Tokai J Exp Clin Med; 2000 Jun; 25(2):69-77. PubMed ID: 11127510
[TBL] [Abstract][Full Text] [Related]
14. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
15. Profile of p53 expression in bladder and oral tumours. Effects of in vitro manipulations of p53 on the behaviour of established human tumour cell lines.
Nouri AM; Cannell H; Dagini B; Dabare AA; Habib N; Fowler CG
Eur J Cancer; 2000 Sep; 36(14):1853-62. PubMed ID: 10974634
[TBL] [Abstract][Full Text] [Related]
16. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
17. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
[TBL] [Abstract][Full Text] [Related]
18. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
[TBL] [Abstract][Full Text] [Related]
19. TP53 intronic mutations in bovine enzootic hematuria-associated urinary bladder tumors.
Sasani F; Baghban F; Nikbakht Brujeni GH; Kazemi M
Vet Pathol; 2013 May; 50(3):543-7. PubMed ID: 23242803
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
